Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-22T18:01:54.127Z Has data issue: false hasContentIssue false
  • English
  • Français

Penicillamine and Schizophrenia—A Clinical Trial

Published online by Cambridge University Press:  29 January 2018

J. W. Affleck ,
A. J. Cooper ,
A. D. Forrest ,
J. R. Smythies  and
A. K. Zealley
J. W. Affleck
Affiliation:
Royal Edinburgh Hospital
A. J. Cooper
Affiliation:
Department of Psychiatry, University of Edinburgh Hospital
A. D. Forrest
Affiliation:
Royal Edinburgh Hospital
J. R. Smythies
Affiliation:
Department of Psychiatry, University of Edinburgh
A. K. Zealley
Affiliation:
Royal Edinburgh Hospital Morningside Park, Edinburgh, 10
Get access Rights & Permissions [Opens in a new window]

Extract

One specific hypothesis concerning the biochemical lesion in schizophrenia was put forward by McIsaac (1961) on the basis of the close chemical relationship between the pineal hormone melatonin and the hallucinogenic drug harmine. On this basis Nicholson et al. (1966) conducted a clinical trial of D-penicillamine plus a low copper diet in schizophrenics, with encouraging results. They used 1,200 mg. daily in a double-blind trial against placebo for six weeks. Hollister et al. (1966) also treated schizophrenic patients with D-penicillamine, but for a different reason—they suggested that depolymerization might be effective if schizophrenia is an autoimmune disorder. They used doses of 1,000 mg. daily for five weeks following an initial build up, and noted no clinical amelioration in 13 schizophrenics studied. A normal diet was given. Walshe (1967) failed to find any improvement in 4 chronic patients on penicillamine for one year.

Type
Studies in Schizophrenia
Information
The British Journal of Psychiatry , Volume 115 , Issue 519 , February 1969 , pp. 173 - 176
Copyright
Copyright © Royal College of Psychiatrists, 1969 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chassan, J. (1960). “Statistical inferences and the single case in clinical design.” Psychiat., 23, 173–184.CrossRefGoogle Scholar
Chassan, J. (1961). “Stochastic models of the single case as the basis of clinical research design.” Behav. Sci., 6, 42–50.CrossRefGoogle Scholar
Hamilton, M., Smith, A. L. G., Lapidus, H. E., and Gadogan, E. P. (1960). “A controlled trial of thiopro-pazate dihydrochloride (Dartalan), chlorpromazine and occupational therapy in chronic schizophrenics.” J. ment. Sci., 106, 40–55.CrossRefGoogle Scholar
Hollister, L. E., Moore, F. F., Forrest, F., and Bennett, J. L. (1966). “Anti-pyridoxine effect of d-pencillamine in schizophrenic men.” Amer. J. clin. Nutr., 19, 307–312.CrossRefGoogle Scholar
McIsaac, W. M. (1961). “A biochemical concept of mental disease.” Postgrad. Med., 30, 111–118.CrossRefGoogle Scholar
McPherson, F. M., and Le Gassicke, J. (1965). “A single-patient self-controlled and self-recorded trial of WY 3498.” Brit. J. Psychiat., 111, 149–151.CrossRefGoogle Scholar
Nicholson, G. A., Greiner, A. C., McFarlane, W.J. B., and Barker, R. A. (1966). “Effect of penicillamine on schizophrenic patients.” Lancet, i, 344–347.CrossRefGoogle Scholar
Walshe, J. M. (1967). “A study of copper transport in schizophrenia.” In: Molecular Basis of some Aspects of Mental Activity (Walaas, O., ed.). London: Academic Press.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.